Clearside Biomedical Files 8-K for Other Events
Ticker: CLSDQ · Form: 8-K · Filed: Oct 7, 2025 · CIK: 1539029
| Field | Detail |
|---|---|
| Company | Clearside Biomedical, Inc. (CLSDQ) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, other-events
TL;DR
Clearside Biomedical filed an 8-K for 'Other Events' on Oct 7, 2025. Details TBD.
AI Summary
On October 7, 2025, Clearside Biomedical, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure, with no specific details provided regarding the nature of these events in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Alpharetta, Georgia.
Why It Matters
This filing signals that Clearside Biomedical has reported an event of significance to the company, though the specific nature of the event is not detailed in this excerpt.
Risk Assessment
Risk Level: medium — The lack of specific detail in the 'Other Events' category creates uncertainty about the nature and potential impact of the reported event.
Key Numbers
- 001-37783 — Commission File Number (Identifier for Clearside Biomedical's SEC filings)
- 45-2437375 — IRS Employer Identification No. (Tax identification number for Clearside Biomedical)
Key Players & Entities
- Clearside Biomedical, Inc. (company) — Registrant
- October 07, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Alpharetta, Georgia (location) — Principal Executive Offices
- 900 North Point Parkway Suite 200 (address) — Principal Executive Offices Address
FAQ
What specific event(s) are being reported under 'Other Events' by Clearside Biomedical?
The provided text does not specify the nature of the 'Other Events' reported by Clearside Biomedical on October 7, 2025.
When was this 8-K filing submitted?
The filing was submitted on October 7, 2025.
What is Clearside Biomedical's primary business classification?
Clearside Biomedical, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where are Clearside Biomedical's principal executive offices located?
Clearside Biomedical's principal executive offices are located at 900 North Point Parkway, Suite 200, Alpharetta, Georgia, 30005.
What is the Commission File Number for Clearside Biomedical?
The Commission File Number for Clearside Biomedical, Inc. is 001-37783.
Filing Stats: 663 words · 3 min read · ~2 pages · Grade level 13 · Accepted 2025-10-07 16:10:26
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar
- $1.00 — ired to maintain a closing bid price of $1.00 per share or more for at least 10 conse
Filing Documents
- clsd-20251007.htm (8-K) — 43KB
- 0001193125-25-233470.txt ( ) — 146KB
- clsd-20251007.xsd (EX-101.SCH) — 24KB
- clsd-20251007_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On October 6, 2025, Clearside Biomedical, Inc. (the " Company ") received a letter from the Nasdaq Hearings Panel (the " Panel ") notifying the Company that it has regained compliance with the Minimum Bid Price Requirement (as defined below). Accordingly, the Panel determined that the Company has regained compliance with Nasdaq's Listing Rules. To regain compliance with the Minimum Bid Price Requirement, the Company's common stock was required to maintain a closing bid price of $1.00 per share or more for at least 10 consecutive business days. As previously disclosed, on February 7, 2025, the Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (" Nasdaq ") notifying the Company that it was non-compliant with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company's common stock was less than $1.00 per share for the previous 30 consecutive business days (the " Minimum Bid Price Requirement "). As the Company did not regain compliance with the Minimum Bid Price Requirement within the 180-calendar day grace period set forth by Listing Rule 5810(c)(3)(A) by August 6, 2025, Nasdaq notified the Company by letter dated August 11, 2025, that the Company's securities are subject to delisting from Nasdaq unless the Company timely requested a hearing before a Panel. The Company submitted a timely request for a hearing before the Panel, which automatically stayed any suspension or delisting of the Company's securities. On September 16, 2025, the Company attended its hearing before the Panel, during which it presented its plan to regain compliance with the Minimum Bid Price Requirement, which included the implementation of a stockholder-approved reverse stock split effective on September 12, 2025. As noted above, this matter is now closed since the Company is now compliant with all applicable Nasdaq continued listing rules.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 7, 2025 CLEARSIDE BIOMEDICAL, INC. By: /s/ Charles A. Deignan Name: Charles A. Deignan Title: Chief Financial Officer